Home > Education Hub > Medtech CDMO: Market and M&A Global Trends in 2024

Medtech CDMO: Market and M&A Global Trends in 2024

Webinar Replay

Despite a strenuous past year in the medtech industry, the global medtech contract development and manufacturing (CDMO) market has continued to grow steadily, reaching $81.5B in 2023. Over half of worldwide industry revenues can be attributed to the resilient performance of more than 600 CDMOs across European and US markets.

This webinar investigates the current state of the global medtech CDMO industry and highlight Europe as a promising frontier for consolidation. Attendees will get key insights surrounding this dynamic market, including:

The market trends that impact the performance of global medtech CDMOs today
An assessment of Western Europe’s CDMO landscape that identifies the region’s core capabilities and end markets
A 2024 outlook for medtech CDMOs that contextualizes mergers and acquisitions (M&A) activity from 2023 with expected market opportunities and risks

This webinar marks the release of Alira Health’s annual 2024 Global Medtech Contract Manufacturing Report.

The webinar is hosted by MassMEDIC, the largest regional medtech association in the United States, with over 300 members representing manufacturers, product developers, suppliers, research institutions and academic health centers.

Our Speakers

Webinars

Category:

CDMO MedTech

Published on:

January 31, 2024

Carlo Stimamiglio

Partner, Transaction Advisory Services Carlo engages with Alira Health’s strategy consulting and M&A mandates for medtech, capital equipment, and pharmaceutical companies in the U.S. and Europe. Prior to joining Alira Health, Carlo worked at a multi-billion Italian asset management firm and later joined an investment banking boutique, where he advised mid-market private equity firms in various international transactions. Carlo holds an MS in Finance from the University of Verona and an MBA from IE Business School.

Sofia Puzzi

Manager, Transaction Advisory Services Sofia focuses on medtech M&A deals, capital raisings, and pharmaceutical licensing. She holds a MSc in Management from ESSEC Business School, in France, with a major in Strategic Consulting and Therapeutic Innovation and a BSc in Business Economics from Bocconi University, in Italy. She is an investment banking representative, holding FINRA Series 79 license.